626 results about "Solid-phase synthesis" patented technology

The invention provides a tripeptide for promoting bone growth, the tripeptide is VPF, the amino acid sequence of the tripeptide is Val-Pro-Phe, the molecular weight of the tripeptide is 361.44 Da, and the tripeptide belongs to the technical field of functional bioactive peptides. The tripeptide can be prepared from egg yolk protein through enzymolysis separation and purification, can also be obtained through chemical solid-phase synthesis, has a good effect of promoting bone growth, can remarkably improve the growth and proliferation level of osteoblasts in a body, promotes synthesis and secretion of bone matrixes, and has a good application prospect. Meanwhile, the secretion of insulin-like growth factors (IGF-1), transforming growth factors (TGF-beta1) and I-type procollagen amino-terminal peptide (PINP) in the body is efficiently promoted, and good market prospects are achieved.

The invention relates to the technical field of preparation methods of polypeptide drugs, and provides a solid-phase preparation method of tirpotide, which comprises the following steps: by taking amino resin as initial resin, sequentially coupling amino acid and small-fragment peptide according to an amino acid sequence of the tirpotide by using a solid-phase synthesis method to synthesize tirpotide resin; and cracking and purifying the tilpotide resin to obtain a pure tilpotide product. Wherein the small fragment peptide is 1-4 tetrapeptide fragment Boc-Tyr (tBu)-Aib-Glu (OtBu)-G1y-OH, 5-6 dipeptide fragment Fmoc-Thr (tBu)-Phe-OH, 7-8 dipeptide fragment Fmoc-Thr (tBu)-Ser (tBu)-OH, 10-11 dipeptide fragment Fmoc-Tyr (tBu)-Ser (tBu)-OH, 12-13 dipeptide fragment Fmoc-Ile-Aib-OH, 17-18 dipeptide fragment Fmoc-Lys (AEEA-AEA-gamma-Glu (alpha-OtBu)-Ecosanoic acid (mon-tBu), 20 side chain peptide Fmoc The coupling agent coupling the amino acid and the small fragment peptide is selected from the group consisting of Oxyma and DIC, TPTU and TMP or COMU and DIEA. The crude product of the tirpotide prepared by the method disclosed by the invention is high in yield and high in purity.

The invention provides a tetrapeptide for promoting bone growth, the amino acid sequence of the tetrapeptide is Glu-Pro-Gly-Phe (EPGF), the molecular weight of the tetrapeptide is 448.48 Da, the tetrapeptide can be prepared from egg yolk protein through protease enzymolysis, separation and purification and can also be obtained through chemical solid-phase synthesis, and the tetrapeptide belongs to the technical field of functional bioactive peptides. The tetrapeptide prepared by the invention can promote the growth of osteoblasts in a body and improve the secretion level of insulin-like growth factor-1 (IGF-1), transforming growth factor-beta1 (TGF-beta1) and I-type procollagen amino terminal peptide (PINP) in cells, so that the effect of promoting bone growth is achieved, and a new functional component is provided for a product for improving bone growth.

The invention provides a solid-phase synthesis method of semeglutide, and belongs to the technical field of synthesis of medical intermediates, and the method specifically comprises the following steps: segmenting a semeglutide main chain into three shorter polypeptide fragments, namely a fragment 4, a fragment 5 and a fragment 2, which are 7-14 sites, 15-22 sites and 23-37 sites; and respectively synthesizing and then assembling fragments to obtain a target product. The method specifically comprises the following steps: a) synthesizing a 7-14 peptide fragment and a 15-22 peptide fragment, and assembling the 7-14 peptide fragment and the 15-22 peptide fragment into a 7-22 peptide fragment, namely a fragment 1; b) synthesizing a 23-37 peptide fragment, selectively removing a protecting group A11oc on Lys26, and connecting with a side chain to form a fragment 3; c) connecting the peptide fragment 7-22 with the peptide fragment 23-37, and removing a protecting group to obtain a crude product; and d) separating and purifying to obtain a finished product. According to the invention, the purpose of high-purity, high-yield and low-cost synthesis of the semeglutide bulk drug can be achieved.

Polymers synthesized by solid-phase synthesis are selectively released from a solid support by reversing the bias of spatially addressable electrodes. Change in the current and voltage direction at one or more of the spatially addressable electrodes changes the ionic environment which triggers cleavage of linkers that leads to release of the attached polymers. The spatially addressable electrodes may be implemented as CMOS inverters embedded in an integrated circuit (IC). The IC may contain an array of many thousands of spatially addressable electrodes. Control circuity may independently reverse the bias on any of the individual electrodes in the array. This provides fine-grained control of which polymers are released from the solid support. Examples of polymers that may be synthesized on this type of array include oligonucleotides and peptides.

The invention discloses a cyclic peptide compound as well as a preparation method and application thereof, belongs to the field of polypeptide synthesis and application, and particularly relates to full-protection peptide resin prepared by solid-phase synthesis. Carrying out cutting and monocyclization on the full-protection peptide resin to obtain monocyclic peptide; the monocyclic peptide is subjected to binary cyclization treatment to obtain a cyclic peptide compound Cyclo (His-Lys-Cys-Gly-His-Lys-Cys-Gly-, and a disulfide bond is in bridge connection with Cysamp; and the binary cyclization is cyclized under the action of iodine methanol and ascorbic acid. The cyclopeptide compound prepared by the invention has the advantages of low toxicity, good stability, good antioxidant effect and good anti-inflammatory effect, and the expression of type I collagen can be improved. Therefore, the invention has the advantages of low toxicity, good stability, good antioxidant effect and good anti-inflammatory effect, and can improve the expression of the type I collagen.

The present invention relates to a molecular imaging probe for tumor diagnosis, and provides a sugar nucleic acid molecular imaging probe, the probe comprises a DNA aptamer sequence and more than one glycosyl nucleoside module, and is labeled by radionuclide, the DNA aptamer sequence can specifically target tumor cells after functional folding; the glycosyl nucleoside module is a glycosyl modified nucleoside derivative, is accurately modified at the 5'end or / and the 3 'end of the aptamer through DNA solid-phase synthesis, has the imaging characteristics of biological safety, high sensitivity and high resolution, and has an excellent diagnosis effect on part of cancers which are difficult to diagnose by a traditional method. The invention also provides a preparation method and a use method of the sugar nucleic acid molecular imaging probe, so that sugar modification of the aptamer is convenient, rapid, accurate, controllable and modularized, and the sugar nucleic acid molecular imaging probe has huge clinical application potential and transformation value in cancer diagnosis.

The invention discloses a scorpion anti-inflammatory polypeptide as well as a screening method and application thereof, and belongs to the technical field of traditional Chinese medicinal material polypeptides. The scorpion anti-inflammatory polypeptide is one of G4, G5 and G17. The method comprises the following steps: detecting a scorpion buthus martensii polypeptide extract through nanoElute 2 nanoliter liquid phase separation, timsTOFPro2 mass spectrometry and BPS Novor search analysis, screening a scorpion buthus martensii polypeptide, and further synthesizing the screened candidate polypeptide by adopting a solid-phase synthesis method; the effect of the synthesized candidate polypeptide on inhibiting microglial cell inflammation is evaluated through a qPCR method, and then the scorpion buthus martensii anti-inflammatory polypeptide is screened out. The Buthus martensii Karsch anti-inflammatory polypeptides G4, G5 and G17 screened by the method, especially G5, can significantly inhibit microglial cell inflammation and present concentration dependence, a theoretical basis is provided for medicinal development of Buthus martensii Karsch polypeptides, and a potential anti-neuroinflammation mechanism of the Buthus martensii Karsch polypeptides is disclosed.

The invention discloses a split intein and application thereof, the split intein comprises two independent peptide fragments: (a) an N-terminal fragment, the amino acid sequence of which is as shown in SEQ ID NO.1; (b) a C-terminal fragment or a variant thereof, the amino acid sequence of the C-terminal fragment is as shown in SEQ ID NO.2, and the amino acid sequence of the variant is as shown in SEQ ID NO.3 or SEQ ID NO.4. The split intein has splicing activity and excellent splicing rate, the application of the split intein can be widened, the number of amino acids of the C-terminal fragment or the variant thereof is small, and the split intein has remarkable advantages in protein purification, solid-phase synthesis and the like.

The invention discloses a tortoise shell bioactive peptide and a preparation method and application thereof.The tortoise shell bioactive peptide comprises one or more of EHTVVY, GPKKDQK, SPLSDVRGH, SENADKGALS and DPKMNGLK. The preparation method comprises the steps of preparation of tortoise shell protein hydrolysate, ultrafiltration separation, anion exchange resin separation, gel column separation, de novo sequencing analysis, molecular docking screening and solid-phase synthesis. The tortoise shell bioactive peptide can be applied to the fields of oxidation resistance and immunoregulation. The method disclosed by the invention is a separation, purification and identification technical method of the tortoise shell specific antioxidant polypeptide based on activity guidance, and has the advantages of clear components, clear activity, clear mechanism and the like; the obtained specific polypeptide has important significance for functional product development of polypeptide compounds with clear tortoise shell components.

The invention discloses a BimBH3 analogue containing D-type amino acid and N-terminal fatty acid acylation, a preparation method of the BimBH3 analogue and application of the BimBH3 analogue as a PTPN1 inhibitor to development of hypoglycemic drugs. The structural general formula of the novel BimBH3 mimic peptide analogue is shown as a formula I: # imgabs0 #, wherein Raa2 is equal to D-His, D-Leu, D-Pro, D-Ser, D-Arg, D-Gln, D-Lys, D-Trp, D-Val, D-Tyr, D-Ala, Raa3 is equal to D-Gln, Raa7 is equal to D-Arg, and Raa8 is equal to D-Allo-Ile. The mimic peptide compound is derived from a core region of a Bim-BH3 structural domain, different D-type amino acid site-specific replacement modification and N-terminal conjugated hexadecanoic acid modification are adopted for amino acids at the second, third, seventh and eighth sites respectively, the BimBH3 mimic peptide modified by the D-type amino acid is more stable and has higher metabolic stability, and the target binding capacity and inhibitory activity of the BimBH3 mimic peptide can still be reserved or even improved. The BimBH3 mimic peptide compound shows an excellent PTPN1 inhibitor, the ability of resisting protease hydrolase and various digestive enzymes is also remarkably improved, and the BimBH3 mimic peptide compound has longer pharmacological action time and can play a potential long-acting hypoglycemic role through subcutaneous injection or oral administration. The compound is completely prepared by a polypeptide solid-phase synthesis method, and an obtained crude product is subjected to semi-preparative liquid chromatography purification and freeze-drying to obtain a target compound.

According to the portable solid-phase synthesis reaction device, in the portable solid-phase synthesis reaction device, a support module comprises a synchronous belt lead screw nut; the motor driving module is installed on one side of the upper end edge of the support module to serve as a power source component for adjusting the size of the composite column cavity, the motor driving module comprises a stepping motor and a synchronous wheel, the synchronous wheel is installed on an output shaft of the stepping motor, and the synchronous belt is arranged on the synchronous wheel and the synchronous belt lead screw nut in a sleeving mode; the lead screw lifting module is installed on the column top support to serve as an execution component for adjusting the size of the composite column cavity and comprises a transmission lead screw, a piston unit is installed at the lower end of the transmission lead screw, and the transmission lead screw is in threaded connection with a synchronous belt lead screw nut. The synthesis column body module is mounted in the middle between a column top support and a bottom plate of the support module to serve as a synthesis carrier to be filled and a solid-phase synthesis reaction vessel, and the synthesis column body module comprises a synthesis column.

The invention discloses a tyrosinase inhibitory peptide from kelp as well as a preparation method and application of the tyrosinase inhibitory peptide. The preparation method comprises the following steps: pretreating kelp, fermenting the kelp by using lactobacillus plantarum, carrying out centrifugation, ultrafiltration and component identification on the obtained fermentation liquor to obtain the composition of kelp polypeptide, screening the tyrosinase inhibitory peptide through molecular docking, and finally carrying out solid-phase synthesis to obtain the tyrosinase inhibitory peptide prepared by the invention. The lactobacillus plantarum fermentation technology is simple and feasible, the production cost is low, equipment is easy to obtain, active ingredients in kelp can be released to the maximum extent, and the prepared polypeptide has the effect of inhibiting the activity of tyrosinase and can be used for developing a tyrosinase inhibitor.

The invention provides an enzymolysis preparation method of a milk-derived taste enhancing peptide, which comprises the following steps: carrying out enzymolysis on a liquid dairy product by using flavourzyme and glutaminase, and then carrying out enzyme deactivation to obtain an enzyme-deactivated product; carrying out acidification centrifugation and ultrafiltration on the enzyme-deactivated product, and freeze-drying the separated effluent to obtain freeze-dried powder; and loading the freeze-dried powder, and separating by a glucose gel column. The product disclosed by the invention does not generate bitter taste, and compared with a sample which is not subjected to enzymolysis, the flavor level of an original skimmed milk product is enriched, and the sample subjected to enzymolysis has the mellow taste of caramel and frankincense. The method comprises the following steps: separating milk-derived taste active peptides from milk-derived taste active peptides, predicting delicate flavor, anti-oxidation and anti-inflammatory activity and ACE blood pressure lowering functional activity of separated peptide liquid through a model, performing taste verification on the peptides predicted to have taste activity through Fmoc solid-phase synthesis, and performing sensory verification on the milk-derived taste active peptides LSFD, EDIKQME, IKQMEAE and TEDELQDK after synthesis, so that the milk-derived taste active peptides are obtained for the first time and are subjected to sensory verification.

This invention belongs to the field of biomedical technology and discloses a method for targeting GABA. A The receptor-dependent cyclic peptide analgesic DZ2 has the following amino acid sequence: Cys-Asn-Thr-Glu-Arg-Pro-Gly-Met-Leu-Asp-Phe-Lys-Gly-Lys-Ala-Lys-Trp-Asp-Ala-Trp-Cys, where the N-terminal Cys and C-terminal Cys are cyclically linked by a disulfide bond, and the molecular weight is 2454.81 g / mol. This cyclic peptide can be obtained through classic Fmoc-solid-phase synthesis, using GABA... A Receptor-targeting drugs play an important role in drug development. The compounds provided in this invention can activate GABA. A The receptor generates a GABA-like inward current. Furthermore, DZ2 exhibits excellent analgesic effects in a mouse pain model, providing a potential alternative for GABA-based analgesics. A This provides new ideas and theoretical basis for the development of receptor-based analgesics.

The invention discloses an anti-aging and anti-oxidation bicyclic peptide compound as well as a preparation method and application thereof, belongs to the technical field of polypeptide compound synthesis, and particularly relates to full-protection peptide resin prepared by solid-phase synthesis. Carrying out cutting and unitary cyclization on the full-protection peptide resin to obtain unitary cyclic peptide; carrying out binary cyclization treatment on the unitary cyclic peptide to obtain a bicyclic peptide compound Cyclo (His-Cys-Lys-Gly-His-Cys-Lys-Gly-, and bridging a disulfide bond with Cysamp; the binary cyclization comprises cyclization under the action of iodo methanol and ascorbic acid; or the binary cyclization is cyclized in DMSO (Dimethylsulfoxide). The anti-aging and anti-oxidation bicyclic peptide compound prepared by the preparation method disclosed by the invention has the following beneficial effects of low toxicity, good stability, capability of improving I-type collagen expression, good anti-oxidation effect and good anti-inflammatory effect.

The invention discloses a hexapeptide TE6 with xanthine oxidase inhibitory activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptides. The amino acid sequence of the hexapeptide TE6 is TIATVE, and the hexapeptide TE6 can be prepared through a solid-phase synthesis method and an enzymolysis method. The hexapeptide TE6 is identified from a solieria cavaleriei proteolysis solution and has potential interaction with xanthine oxidase, under the concentration of 0.1 mg / mL, the xanthine oxidase inhibition rate is 44.74%, and compared with goose carnosine (the xanthine oxidase inhibition rate is 36.03%), the xanthine oxidase inhibition rate is remarkably increased (plt; 0.05), which is stronger in xanthine oxidase inhibitory activity, and can be used for preparing a preparation for inhibiting xanthine oxidase activity and relieving hyperuricemia.

The invention belongs to the technical field of biology, and particularly relates to polypeptide for promoting proliferation of mesenchymal stem cells and application of the polypeptide. The amino acid sequence of the polypeptide for promoting proliferation of the mesenchymal stem cells is shown as SEQ ID NO: 1. The active polypeptide for promoting proliferation of the umbilical cord mesenchymal stem cells is obtained by adopting a solid-phase synthesis method. Umbilical cord mesenchymal stem cells obtained by culturing the polypeptide have good adherence and multiplication capacities. In addition, the polypeptide can promote Nrf2 gene expression, so that proliferation of the umbilical cord mesenchymal stem cells is effectively promoted.

The invention relates to a molecular tag DMDPM compound, a preparation method thereof and application of the molecular tag DMDPM compound in assisting homogeneous synthesis of heptapeptide H6K, and belongs to the technical field of organic synthesis. The molecular tag DMDPM compound is 2, 4-dimethoxy-4 '-diphenylphosphinyl oxydiphenyl alcohol, and the molecular tag DMDPM compound is 2, 4-dimethoxy-4'-diphenylphosphinyl The method has the advantages of a liquid-phase synthesis method and a solid-phase synthesis method, H6K can be simply, quickly, economically and efficiently synthesized and prepared, and a 2, 4-dimethoxy-4 '-diphenylphosphinyloxy diphenyl alcohol small-molecule auxiliary group (also called as a carrier) can be recycled and directly reused, so that raw material waste is reduced, waste pollution is reduced, the cost is saved, and environmental protection is facilitated.

The present invention discloses a class of bicyclic peptide compounds and their applications, belonging to the technical field of bicyclic peptide compounds. Specifically, the invention relates to the preparation of a fully protected peptide resin using solid-phase synthesis; cleavage and monocyclic cyclization of the fully protected peptide resin to obtain a monocyclic polypeptide; and dicyclic cyclization of the monocyclic polypeptide to obtain a bicyclic peptide compound, wherein the dicyclic cyclization is carried out under the action of iodine methanol and ascorbic acid. The bicyclic peptide compound prepared by the present invention has the following beneficial effects: good safety, low cytotoxicity, good stability, slow degradation rate, good effect on enhancing collagen expression, good effect on enhancing elastin expression, and good effect on inhibiting neurotransmitter release.

The invention discloses a synthesis method of an insulin analogue, which comprises the following steps of: firstly, obtaining A-chain peptide resin by using a solid-phase synthesis method, constructing a disulfide bond between A6 and A11 on a solid phase, and cracking the A-chain peptide resin by using a cracking solution containing a sulfydryl activator to obtain a peptide chain with an activated sulfydryl group and a protected sulfydryl group; then a solid-phase synthesis method is used for obtaining B-chain peptide resin, Lys side chain protecting groups are removed on a solid phase in a fixed-point mode, side chain fatty acid modification is completed, and a peptide chain with an exposed sulfydryl group and a protected sulfydryl group is obtained after cracking is conducted through a cracking solution; and mixing the products in a solution according to a certain proportion to form a first pair of intermolecular disulfide bonds, and constructing and purifying the last pair of disulfide bonds to obtain the insulin analogue. The method disclosed by the invention has the advantages of convenience in synthesis, low cost, simple process and the like, can be used for research on amino acid mutation of insulin compounds, and has important practical significance on development of insulin drugs.

The invention discloses a sodium ion battery single crystal positive electrode material and a preparation method and application thereof, and the material realizes high working voltage, excellent cycling stability and rate capability by accurately controlling chemical composition and microstructure. According to the preparation method, the problem that part of doped metal ions cannot be synthesized into the precursor through a coprecipitation method or synthesized into the precursor in a high proportion can be solved, the microstructure and element distribution uniformity of the material can be effectively controlled, and the performance is more excellent than that of a conventional multi-component oxide mechanical solid-phase synthesis method; the addition of the molten salt can optimize the single crystal morphology and reduce the sintering temperature, the doping of the M element can stabilize the structure and improve the air stability and the cycling stability under high voltage, and the coating of the oxygen-containing compound can reduce the side reaction of the positive electrode material and an electrolyte interface and the electrochemical performance under high voltage. The first-circle discharge specific capacity is 173.34 mAh / g, and the capacity retention ratio is still 91.5% after 100 times of cyclic charge and discharge.

The invention discloses an atomic-scale catalyst for laser solid-phase synthesis as well as a preparation method and application of the atomic-scale catalyst. The preparation method comprises the steps that a solid-phase reaction system is formed, the solid-phase reaction system comprises a carbon-based material with a plurality of anchoring points on the surface and a metal salt precursor loaded on the carbon-based material, and the metal salt precursor is combined with the anchoring points; and carrying out laser irradiation on the solid-phase reaction system, so that the metal salt precursor is reduced to form the atomic-scale catalyst. The atomic-scale catalysts prepared by the method are diversified and comprise monatomic catalysts, diatomic catalysts, monatomic alloys, diatomic alloys, atomic clusters and the like. The preparation method is simple in process, high in universality and suitable for various carbon-based materials containing anchoring points and metal elements with catalytic activity, atomic-scale catalysts can be produced in batches, and the requirements for various catalysts in the fields of chemical industry, petroleum processing industry, energy, pharmaceutical industry, environmental protection and the like can be met.

The invention discloses a water-based synthesis method of mu-conotoxin KIIIA with an instant wrinkle removal effect, and belongs to the technical field of biological medicines. A solid-phase synthesis method is adopted, H-RINK amide CHEMMATRIX resin is used as a solid-phase synthesis carrier, amino acid residues protected by substituent groups are sequentially condensed in an acetonitrile aqueous solution according to the sequence of amino acids from the C end to the N end of a main chain of mu-conotoxin KIIIA, and reduced crude polypeptide is obtained; and carrying out oxidative cyclization on the reduced crude polypeptide in an aqueous solution containing trihydroxymethyl aminomethane hydrochloride, guanidine hydrochloride, reduced glutathione and oxidized glutathione to obtain the mu-conotoxin KIIIA. The method is simple in process, environment-friendly, low in cost, low in chemical waste yield and high in yield (22-27%).

The invention relates to the technical field of dielectric ceramic powder preparation processes, in particular to a multilayer ceramic capacitor, high-activity nano barium titanate powder for the multilayer ceramic capacitor and a preparation method of the high-activity nano barium titanate powder, and the method comprises the following steps: (1) reacting soluble barium salt with a precipitator to obtain barium carbonate precursor particles with high specific surface area; (2) uniformly coating the surfaces of the barium carbonate precursor particles with nano titanium dioxide particles by using a supercritical fluid flash evaporation technology to form a composite precursor; and (3) carrying out solid-phase synthesis reaction on the composite precursor, and sintering to obtain the nano barium titanate powder. Through the synergistic effect of two means of high-activity precursor preparation and nanoscale uniform coating, the composite precursor with extremely high specific surface area, surface energy and microcosmic uniformity is prepared, the thermal sintering temperature is effectively reduced, abnormal growth of crystal grains and lattice distortion are restrained, and the preparation method has the advantages that the preparation process is simple, and the preparation cost is low. The tetragonality of the nano barium titanate powder is obviously improved.

The present application relates to the technical field of dielectric ceramic powder preparation, and particularly relates to a multilayer ceramic capacitor, a high-activity nano-barium titanate powder for the multilayer ceramic capacitor and a preparation method of the high-activity nano-barium titanate powder, the method comprising the following steps: (1) reacting a soluble barium salt with a precipitator to obtain barium carbonate precursor particles with high specific surface area; (2) uniformly coating nano-titanium dioxide particles on the surface of the barium carbonate precursor particles by using a supercritical fluid flash technology to form a composite precursor; and (3) performing a solid-phase synthesis reaction on the composite precursor and sintering to obtain nano-barium titanate powder. The present application, through the synergistic effect of the two means of "high-activity precursor preparation" and "nano-level uniform coating", prepares a composite precursor with extremely high specific surface area, surface energy and micro-uniformity, effectively reduces the heat sintering temperature, suppresses abnormal grain growth and lattice distortion, and significantly improves the tetragonality of the nano-barium titanate powder.

The invention discloses a continuous flow automatic polypeptide solid phase synthesis device which comprises a synthesis unit, a liquid storage unit, a waste output unit, a product bottle and a control unit, and the synthesis unit comprises a microchannel reactor, a washer, a circulating pump, a draw-off pump, a check valve and a product delivery pump; the liquid storage unit is connected with the draw-off pump, the draw-off pump is connected with the micro-channel reactor, the check valve is installed at the input end of the micro-channel reactor, the micro-channel reactor is connected with the washer, the waste output end of the washer is connected with the waste output unit, and the product output end of the washer is connected with the circulating pump and the product conveying pump. The circulating pump is connected to the micro-channel reactor, and the product conveying pump in the last synthesis unit is connected with the product bottle; and the control unit is connected with the circulating pump, the draw-off pump, the check valve, the product conveying pump and the waste output unit. The invention further discloses a continuous flow automatic polypeptide solid-phase synthesis method, and automatic polypeptide production is achieved.

The invention provides semeglutide, which is synthesized by adopting the following method, and the specific steps are as follows: 1) segmenting the main chain of semeglutide into three polypeptide fragments: 7-14 sites, 15-22 sites and 23-37 sites; (2) respectively preparing the 7-14-site fragments, the 15-22-site fragments and the 23-37-site fragments through solid-phase synthesis; 3) connecting the 7-14-site fragment with the 15-22-site fragment to form a 7-22-site fragment, and activating the C end of the fragment into active ester; (4) selectively removing an Alloc protecting group of Lys26 in the 23-37-site fragment, and then carrying out fatty acid modification to obtain a modified 23-37-site fragment; 5) in a liquid phase system, coupling the activated 7-22-site fragment and the modified 23-37-site fragment according to a molar ratio of 1: (0.6-1.4) to form a complete polypeptide chain; and 6) removing the protecting group and purifying to obtain a semaglutide finished product. The method provided by the invention can effectively realize high-purity, high-yield and low-cost synthesis of the semeglutide bulk drug.

The invention provides a synthesis method of tilpotide, which comprises the following steps: dividing a target peptide chain into six fragments, and adopting bis (4-C18-C28 alkoxy phenyl) methylamine, 2, 4-bis (18-C28 alkoxy)-benzyl alcohol and NH2-Asp (OTAG)-OR1 as hydrophobic label carriers to assist synthesis. A side chain carboxyl group of aspartic acid is innovatively used as an anchoring position of a hydrophobic label, a new fragment connection route is designed, a full-protection tilpotide conjugate is synthesized through a multi-label synergistic effect, and finally a protecting group and a label are removed by using a TFA lysate. Compared with a solid-phase synthesis method, the method is carried out in a homogeneous reaction, the dosage of amino acid and the condensing agent is reduced to 1-1.2 times from 2-3 times, and the cost is remarkably reduced. Compared with an existing hydrophobic labeling method, the method has the advantages that multiple labels can be introduced to serve as protecting groups, the yield and purity of synthesis of medium-chain and long-chain polypeptides are improved, meanwhile, the problem of hydrophobicity attenuation caused by peptide chain extension is solved, and the green chemical process requirement is met.

The invention relates to the technical field of cultural relic protection materials, in particular to high-activity beta-Ca2SiO4 for cultural relic protection as well as preparation and application of the high-activity beta-Ca2SiO4. On the basis of a traditional solid-phase synthesis process, a novel boron-containing crystal form stabilizer is adopted, high-activity beta-Ca2SiO4 is obtained through high-temperature solid-phase synthesis, or high-activity beta-Ca2SiO4 is obtained through jet mill smashing after high-temperature solid-phase synthesis. The boron-containing crystal form stabilizer with low water solubility is selected, so that on one hand, boron volatilization during high-temperature solid-phase reaction is effectively reduced; and on the other hand, during wet processing, the non-uniform phenomena of crystallization, layering and the like after drying caused by the use of water-soluble crystal stabilizers such as boric acid and sodium borate are effectively avoided. In addition, calcium and calcium-silicon elements contained in the introduced boron-containing crystal form stabilizer are essential components during synthesis of beta-Ca2SiO4, and the content of soluble salt in the high-activity beta-Ca2SiO4 prepared by the method is lower.